GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » ROC %

Prostatype Genomics AB (OSTO:PROGEN) ROC % : -196.57% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Prostatype Genomics AB's annualized return on capital (ROC %) for the quarter that ended in Jun. 2023 was -196.57%.

As of today (2024-06-02), Prostatype Genomics AB's WACC % is 11.48%. Prostatype Genomics AB's ROC % is -137.93% (calculated using TTM income statement data). Prostatype Genomics AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Prostatype Genomics AB ROC % Historical Data

The historical data trend for Prostatype Genomics AB's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB ROC % Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
ROC %
-72.27 -56.89 -87.21 -145.68 -138.69

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -157.05 -171.58 -166.54 -196.57 -

Prostatype Genomics AB ROC % Calculation

Prostatype Genomics AB's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-39.247 * ( 1 - 0% )/( (18.69 + 37.906)/ 2 )
=-39.247/28.298
=-138.69 %

where

Prostatype Genomics AB's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-40.228 * ( 1 - 0% )/( (18.744 + 22.186)/ 2 )
=-40.228/20.465
=-196.57 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB  (OSTO:PROGEN) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Prostatype Genomics AB's WACC % is 11.48%. Prostatype Genomics AB's ROC % is -137.93% (calculated using TTM income statement data). Prostatype Genomics AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Prostatype Genomics AB ROC % Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines